Bayesian assessment of the influence and interaction conditions in multipopulation tailoring clinical trials

Journal of Biopharmaceutical Statistics

Volumn 24, Issue 1, 2014, Pages 94-109

  Millen, Brian A ^a   Dmitrienko, Alex ^b   Song, Guochen ^b  

^a ELI LILLY AND COMPANY   (United States)

^b IQVIA   (United States)

Author keywords

Decision making; Influence condition; Interaction condition; Subgroup analysis; Tailored therapeutics

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; ASTHMA; BAYESIAN LEARNING; CASE STUDY; CLINICAL TRIAL (TOPIC); DECISION MAKING; HUMAN; LUNG CANCER; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; STUDY DESIGN;

ALGORITHMS; ASTHMA; BAYES THEOREM; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; POPULATION; RESEARCH DESIGN;

EID: 84891781670     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543406.2013.856025     Document Type: Article

References (15)

1. Alosh, M., Hugue, M. F. (2013). Multiplicity considerations for subgroup analysis subject to consistency constraint. Biometrical Journal 55:444-462.
2. Berry, S. M., Carlin, B. P., Lee, J. J., Muller, P. (2010). Bayesian Adaptive Methods for Clinical Trials. New York, NY: CRC Press.
3. Food and Drug Administration. (2012). Guidance for industry: Enrichment strategies for clinical trials to support approval of human drugs and biological products. Available at: www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ ucm332181.pdf
4. Freidlin, B., McShane, L. M., Korn, E. L. (2010). Randomized clinical trials with biomarkers: Design issues. Journal of the National Cancer Institute 102:152-160.
5. Freidlin, B., McShane, L. M., Polley, M. C., Korn, E. L. (2012). Randomized Phase II trial designs with biomarkers. Journal of Clinical Oncology 30:3304-3309.
6. Herson, J. (1979). Predictive probability early termination plans for Phase II clinical trials. Biometrics 35:775-783.
7. Jia, G., Erickson, R. W., Choy, D. F., Mosesova, S., Wu, L. C., Solberg, O. D., Shikotra, A., Carter, R., Audusseau, S., Hamid, Q., Bradding, P., Fahy, J. V., Woodruff, P. G., Harris, J. M., Arron, J. R. (2012). Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. Journal of Allergy and Clinical Immunology 130:647-654.
8. Millen, B. A., Dmitrienko, A., Ruberg, S., Shen, L. (2012). A statistical framework for decision making in confirmatory multipopulation tailoring clinical trials. Drug Information Journal 46:647-656.
9. Millen, B. A., Dmitrienko, A., Mandrekar, S. J., Zhang, Z., Williams, D. (2014). Multipopulation tailoring clinical trials: Design, analysis, and inference considerations. Therapeutic Innovation and Regulatory Science. In press.
10. Pennello, G., Thompson, L. (2008). Experience with reviewing Bayesian medical device trials. Journal of Biopharmaceutical Statistics 18:81-115.
11. Rothmann, M. D., Zhang, J. J., Lu, L., Fleming, T. R. (2012). Testing in a pre-specified subgroup and the intent-to-treat population. Drug Information Journal 46:175-179.
12. Sequist, L. V., von Pawel, J., Garmey, E. G. (2011). Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. Journal of Clinical Oncology 29:3307-3315.
13. Simon, R., Wang, S. J. (2006). Use of genomic signatures in therapeutics development in oncology and other diseases. Pharmacogenomics Journal 6:166-173.
14. Spiegelhalter, D. J., Abrams, K. R., Myles, J. P. (2004). Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Chichester: Wiley.
15. Wang, S. J., O'Neill, R. T., Hung, H. M. J. (2007). Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharmaceutical Statistics 6:227-244.